Relationship between degree of P2Y12 receptor blockade and inhibition of P2Y12-mediated platelet functionRobert Buckland, Heather M. Judge, Atsuhiro Sugidachi et al.|Thrombosis and Haemostasis|2010Cited by 78
The active metabolite of prasugrel effectively blocks the platelet P2Y<sub>12</sub>receptor and inhibits procoagulant and pro-inflammatory platelet responsesHeather M. Judge, Robert F. Storey, Robert Buckland et al.|Platelets|2008Cited by 62
Potentiation of clopidogrel active metabolite formation by rifampicin leads to greater P2Y12 receptor blockade and inhibition of platelet aggregation after clopidogrelHeather M. Judge, Robert F. Storey, Shankar B. Patil et al.|Journal of Thrombosis and Haemostasis|2010Cited by 45
Cangrelor inhibits the binding of the active metabolites of clopidogrel and prasugrel to P2Y<sub>12</sub>receptors<i>in vitro</i>Heather M. Judge, Robert F. Storey, Robert Buckland et al.|Platelets|2015Cited by 39
Bioenergetics of acquired cisplatin resistant H1299 non-small cell lung cancer and P31 mesothelioma cellsFintan Geoghegan, Richard K. Porter, Mary F. Rooney et al.|Oncotarget|2017Cited by 15